Submit to FDA a draft protocol for the next study of SER-155 in allo-HSCT in Q2 2025.; Present SER-155 Phase 1b clinical and exploratory translational biomarker data as a Top 100 abstract at the European Bone Marrow Transplant meeting in March 2025, facilitating engagement with potential European investigators in support of the Company’s planned global study. Additionally, exploratory translational biomarker data from across Seres’ programs, including in allo-HSCT and IBD, have been accepted for poster presentations at Digestive Disease Week in May 2025.; Expecting receipt of a $25 million installment payment from Nestle in July 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Positive Outlook for Seres Therapeutics: FDA Endorsement and Strategic Study Design Boost Buy Rating
- Seres Therapeutics receives feedback from FDA on SER-155 development approach
- Seres Therapeutics Announces CMO Resignation in March 2025
- Seres Therapeutics Expands Board with Nestlé’s Appointee
- Seres Therapeutics announces receipt of expected $50M installment payment